StockData
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. (JBIO) stock

JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$15.31+0.25 (+1.66%)

Close on Nov 20, 2026Market cap $973.68MP/E –Yield –

Jade Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Jade Biosciences's free cash flow for the twelve months ending Dec 31, 2025 was -$94.89M. For fiscal 2025 it was -$94.89M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$94.89M–
FY2023Dec 31, 2023-$56.92M–
FY2022Dec 31, 2022-$39.32M–
FY2021Dec 31, 2021-$27.58M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$33.65M–
Q3 FY2025Sep 30, 2025-$22.18M–
Q4 FY2023Dec 31, 2023-$14.86M–
Q3 FY2023Sep 30, 2023-$15.64M–
Q2 FY2023Jun 30, 2023-$14.97M–
Q1 FY2023Mar 31, 2023-$11.44M–
Q4 FY2022Dec 31, 2022-$14.87M–
Q3 FY2022Sep 30, 2022-$9.75M–
Q2 FY2022Jun 30, 2022-$9.01M–
Q1 FY2022Mar 31, 2022-$5.69M–
Q4 FY2021Dec 31, 2021-$13.18M–
Q3 FY2021Sep 30, 2021-$6.58M–
Q2 FY2021Jun 30, 2021-$4.01M–
Q1 FY2021Mar 31, 2021-$3.82M–

More Jade Biosciences figures

See a number that looks wrong?